Core Viewpoint - The company is committed to enhancing quality and efficiency while returning value to investors, aligning with national policies and market demands to drive high-quality development and protect investor rights [1]. Group 1: Strategic Focus and Business Development - The company focuses on the development of medical endoscopes and optical products, emphasizing innovation in optical technology and digital imaging [1]. - In 2024, the company expanded its endoscope product line, obtaining registration certificates for various endoscopes, including thoracic and abdominal endoscopes, hysteroscopes, and bladder endoscopes [1]. - The company has established a remote interactive platform for surgical diagnosis and treatment, integrating automatic microscopic scanning and endoscopic systems [2]. Group 2: Innovation and R&D - The company applied for 42 new patents and received 32 new authorized patents, including 12 invention patents, which account for 37.50% of the newly authorized patents [3]. - The company collaborates with external institutions for innovation, establishing a clinical anatomy training center with a medical college to enhance clinical, research, and educational activities [3]. Group 3: Investor Protection Measures - The company has implemented a stable dividend policy, distributing cash dividends to shareholders for five consecutive years, with a proposed cash dividend of 0.60 yuan per share for 2024 [4][5]. - The company has initiated a share repurchase plan, with a total of 1,387,000 shares repurchased, representing 0.6110% of the total share capital [5][6]. - The company emphasizes high-quality information disclosure and investor communication, ensuring transparency and responsiveness to investor inquiries [6][7]. Group 4: Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and independent directors, ensuring clear responsibilities and coordination [8]. - The company plans to optimize its governance structure in 2025, including revising its articles of association and adjusting internal supervisory mechanisms [8].